Lantern Pharma Inc. Operating Cash Flow
Lantern Pharma Inc. (LTRN) reported Operating Cash Flow of -$6.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Lantern Pharma Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.94M.
- Lantern Pharma Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.77M.
- Lantern Pharma Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.79M.
- Lantern Pharma Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.57M.
- Lantern Pharma Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$15.68M.
- Lantern Pharma Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$17.81M.
- Lantern Pharma Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$14.35M.
- Lantern Pharma Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$12.77M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$6.71M 10-Q · filed 2026-08-14 | -$9.51M derived: sum of 3 quarters · filed 2026-08-14 | -$14.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$3.77M 10-Q · filed 2026-05-15 | -$6.56M derived: sum of 2 quarters · filed 2026-05-15 | -$11.14M derived: sum of 3 quarters · filed 2026-05-15 | -$15.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$7.36M derived: sum of 2 quarters · filed 2026-03-30 | -$11.30M derived: sum of 3 quarters · filed 2026-08-14 | -$15.68M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$4.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$8.51M derived: sum of 2 quarters · filed 2026-08-14 | -$12.88M 10-Q · filed 2025-11-12 | -$16.86M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$8.31M 10-Q · filed 2026-08-14 | -$12.28M derived: sum of 3 quarters · filed 2026-08-14 | -$17.87M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$4.38M 10-Q · filed 2026-05-15 | -$8.35M derived: sum of 2 quarters · filed 2026-05-15 | -$13.93M derived: sum of 3 quarters · filed 2026-05-15 | -$19.12M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$3.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$9.55M derived: sum of 2 quarters · filed 2026-03-30 | -$14.74M derived: sum of 3 quarters · filed 2026-03-30 | -$17.81M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$5.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$10.77M derived: sum of 2 quarters · filed 2025-11-12 | -$13.84M 10-Q · filed 2025-11-12 | -$17.23M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$5.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$8.26M 10-Q · filed 2025-08-13 | -$11.64M derived: sum of 3 quarters · filed 2025-08-13 | -$15.26M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$3.07M 10-Q · filed 2025-05-15 | -$6.45M derived: sum of 2 quarters · filed 2025-05-15 | -$10.07M derived: sum of 3 quarters · filed 2025-05-15 | -$13.66M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$7.00M derived: sum of 2 quarters · filed 2025-03-27 | -$10.59M derived: sum of 3 quarters · filed 2025-03-27 | -$14.35M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$3.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$7.20M derived: sum of 2 quarters · filed 2024-11-07 | -$10.96M 10-Q · filed 2024-11-07 | -$13.63M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$7.35M 10-Q · filed 2024-08-08 | -$10.02M derived: sum of 3 quarters · filed 2024-08-08 | -$14.06M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$3.76M 10-Q · filed 2024-05-09 | -$6.43M derived: sum of 2 quarters · filed 2024-05-09 | -$10.46M derived: sum of 3 quarters · filed 2024-05-09 | -$13.20M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$6.71M derived: sum of 2 quarters · filed 2024-03-18 | -$9.44M derived: sum of 3 quarters · filed 2024-03-18 | -$12.77M 10-K · filed 2024-03-18 |
| 2022-09-30 | -$4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$6.77M derived: sum of 2 quarters · filed 2023-11-08 | -$10.10M 10-Q · filed 2023-11-08 | -$12.14M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$6.06M 10-Q · filed 2023-08-09 | -$8.10M derived: sum of 3 quarters · filed 2023-08-09 | -$12.78M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$3.33M 10-Q · filed 2023-05-09 | -$5.37M derived: sum of 2 quarters · filed 2023-05-09 | -$10.05M derived: sum of 3 quarters · filed 2023-05-09 | -$11.77M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$6.72M derived: sum of 2 quarters · filed 2023-03-20 | -$8.45M derived: sum of 3 quarters · filed 2023-03-20 | -$10.59M 10-K · filed 2023-03-20 |
| 2021-09-30 | -$4.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$6.41M derived: sum of 2 quarters · filed 2022-11-07 | -$8.55M 10-Q · filed 2022-11-07 | -$10.12M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$3.87M 10-Q · filed 2022-08-08 | -$5.44M derived: sum of 3 quarters · filed 2022-08-08 | -$8.33M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$2.14M 10-Q · filed 2022-05-03 | -$3.71M derived: sum of 2 quarters · filed 2022-05-03 | -$6.60M derived: sum of 3 quarters · filed 2022-05-03 | -$7.09M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | -$1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$4.46M derived: sum of 2 quarters · filed 2022-03-10 | -$4.95M derived: sum of 3 quarters · filed 2022-03-10 | -$5.65M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$2.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | -$3.38M derived: sum of 2 quarters · filed 2021-11-01 | -$4.08M 10-Q · filed 2021-11-01 | -$4.79M derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | -$490.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$1.19M 10-Q · filed 2021-07-29 | -$1.90M derived: sum of 3 quarters · filed 2021-07-29 | -$2.45M derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | -$703.05K 10-Q · filed 2021-05-03 | -$1.41M derived: sum of 2 quarters · filed 2021-05-03 | -$1.96M derived: sum of 3 quarters · filed 2021-05-03 | |
| 2019-12-31 | -$708.88K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | -$1.26M derived: sum of 2 quarters · filed 2021-03-10 | -$2.13M 10-K · filed 2021-03-10 | |
| 2019-09-30 | -$549.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$1.42M 10-Q · filed 2020-10-29 | ||
| 2019-06-30 | -$869.12K 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |